December 27, 2013
Ono Pharmaceutical announced on December 24 that it submitted on the same day a new drug application (NDA) for its fully-human IgG4 PD-1 immune checkpoint inhibitor nivolumab for the treatment of malignant melanoma to the Ministry of Health, Labor and...read more